Abstract: The disclosure relates to compositions and methods for treating keratin fibers. Compositions comprise part (A) comprising (a) at least one compound chosen from urea and urea derivatives; and part (B) comprising (b) at least one polyol compound. Methods comprise applying the composition to keratin fibers to provide long-lasting effects such as good curl definition and regularity, better movement and discipline, and/or good volume and frizz control. Kits comprising the composition are also disclosed.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
April 12, 2022
Assignee:
L'OREAL
Inventors:
Marina Tavares Gregolin, Ana Paula Leme De Magalhães, Manon Chaumontet, Sintia Aguiar Martins, Arthur Olimpio De Cunto Carvalho
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Provided are coated particles and methods of their use for providing healthcare benefits. More specifically, the present invention provides amino acid and/or polymer-coated particles, or particles coated with other materials, for binding to, or otherwise associating with, surfaces of the oral cavity.
Type:
Grant
Filed:
May 16, 2018
Date of Patent:
April 5, 2022
Assignee:
Johnson & Johnson Consumer Inc.
Inventors:
Robert Gambogi, Latrisha Petersen, Sherket Peterson, Andrew Glowacki, Meenakshi Patel
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: A topical composition that includes L-arginine that is used as a sports health composition. The composition can further include forskolin. Disclosed is a method of using the topical composition.
Type:
Grant
Filed:
June 19, 2020
Date of Patent:
March 22, 2022
Assignee:
REV PHARMACEUTICALS, INC.
Inventors:
Beth Anne-Szkudlarek Brown, Anthony Lemus, Marnie L. Peterson
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: A conjugate comprising a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, characterised in that the linker includes at least two ˜(CH2—CH2—O—)˜ units within a ring, said ring being attached via a single tethering atom within the ring to the rest of the linker, or said ring being attached via two or more tethering atoms within the ring to the rest of the linker at a single point.
Type:
Grant
Filed:
April 13, 2017
Date of Patent:
March 15, 2022
Assignee:
POLYTHERICS LIMITED
Inventors:
Antony Godwin, Andrew Kyle, Nicholas Evans
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: A lip cosmetic has a high transparency without giving unnatural whiteness and exerts a remarkable effect of ultraviolet ray protection over a broad wavelength range including the UVA and UVB regions. The lip cosmetic includes (A) at least 5% by mass of UV absorbers; wherein said (A) UV absorbers comprises (A1) at least one UV absorber selected from a group consisting of octocrylene, dimethicodiethylbenzalmalonate and diethylamino hydroxybenzoyl hexyl benzoate, and (A2) ethylhexyl methoxycinnamate; (B) a high-viscosity oil component in a range of 30% by mass to 70% by mass thereof; (C) a low-viscosity oil component in a range of 20% by mass to 40% by mass thereof, and (D) titanium dioxide and zinc oxide of which a total content is at most 0.5% by mass thereof; and wherein a sun-protection-factor (SPF) of the lip cosmetic is at least 20, and a critical wavelength thereof is at a shortest 370 nm.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Provision of a material, which has tyrosinase-inhibiting activity and is effective for skin whitening. A tyrosinase inhibitor comprising Syzygium polyanthum or an extract therefrom as an active ingredient is provided. Also, a compound represented by any one of the following formulae (I) to (III) and a tyrosinase inhibitor comprising the compound as an active ingredient are provided.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
August 17, 2021
Assignees:
KAO CORPORATION, BOGOR AGRICULTURAL UNIVERSITY
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: A conjugate of a protein or peptide conjugated to a therapeutic, diagnostic or labelling agent via a linker, in which the linker includes a protein or peptide bonding portion having the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which the linker also includes a cyclodextrin. The invention also provides reagents for making such conjugates.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.